FDA Warning Letters
This article was originally published in The Silver Sheet
Design control and MDR procedures lacking at Edwards Lifesciences; CooperSurgical in the hot seat for inadequate complaint handling activities. Eighteen warning letters listed by FDA from May 14 through June 10.
You may also be interested in...
Mylan and Lupin have revealed when they expect to launch their etanercept biosimilar, Nepexto, in Europe after receiving formal European Commission approval.
The sellers of the anti-aging “cure-all” reached an agreement with the FTC in February that prohibits them from making false and unsubstantiated health claims and requires them to pay $660,000 in total to the Commission. Refund checks now are being issued to more than 1,300 defrauded consumers.
Exits from Pfizer and Gilead as executives move to Oligomerix Inc. and Pandion Therapeutics, respectively, while chief medical officers are appointed at Exicure and Larimar Therapeutics Inc.